Check Your Fridge—Coca-Cola Has Recalled Nearly 900 Cases Of Soda
Before you crack open your next can of Coca-Cola, there's yet another food recall you should absolutely know about. According to a report shared by the U.S. Food & Drug Administration (FDA), select cans of Coca-Cola Original Taste have been voluntarily recalled due to the presence of a foreign object, specifically plastic.
The original recall occurred earlier this month and has since been updated to "Class II" by the FDA. The organization states that a Class II recall is one that "may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote."
Nearly 900 cases of the sodas, which were available in 12-count packs, were recalled from the states of Illinois and Wisconsin. At this point, no other states are included in the recall. The FDA reports that the recalled sodas were bottled and distributed by Reyes Coca-Cola Bottling, LLC, in Milwaukee. For a list of the affected UPC codes, visit the FDA's site.
"Reyes Coca-Cola Bottling is voluntarily recalling 864 cases of 12-pack Coca-Cola Classic in 12-oz cans in Illinois and Wisconsin," a company spokesperson said Wednesday in an emailed statement to USA TODAY. "The cases are being withdrawn because they did not meet our high-quality standards. We are taking this voluntary action because nothing is more important to us than providing high-quality products to the people who drink our beverages."
The FDA has not provided specific advice for handling recalled sodas. However, standard procedure is to, of course, not drink them and return them to the place of purchase for a full refund.
This latest recall serves as just one of many that have occurred due to the presence of a foreign material. Most recently, an assortment of Stouffer's and Lean Cuisine frozen entrées were recalled due to the possible presence of "wood-like" material.
You Might Also Like
Insanely Easy Weeknight Dinners To Try This Week
29 Insanely Delicious Vodka Cocktails
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
39 minutes ago
- USA Today
Smooth savings: Save up to 70% on laser hair removal
Looking for smooth skin and big savings? Look no further than the LaserAway sale. We can all agree that shaving is not a super fun experience. It can be inconvenient and in the worst cases, painful. If you want to skip the razor burn and make your "everything shower" a little less involved, we've got a sale for you. The Back to Basics Sale is officially live at LaserAway, and it is one of the brand's biggest promotions of the year. You can get up to 70% off select laser hair removal packages just in time for all your end-of-summer and early fall events. Whether you're prepping for a big wedding season or just tired of the endless shave cycle, this sale is your chance to invest in smooth, low-maintenance skin at a fraction of the price. What's included in this LaserAway sale? The current sale covers select laser hair removal packages. You can save big on popular treatment areas like: This limited-time offer is great for anyone looking to simplify their beauty routine before the busy fall season kicks in. How do you book an appointment at LaserAway? Booking is easy. Simply visit LaserAway's website to schedule a free consultation and lock in your discount. Appointments are available nationwide and the team will help you customize a treatment plan that fits your goals and budget. Save at LaserAway What is LaserAway? LaserAway is a trusted name in aesthetic dermatology, offering FDA-cleared treatments performed by licensed professionals. Their laser hair removal services are designed for all skin types and use advanced technology to deliver long-lasting results with minimal discomfort.
Axios
an hour ago
- Axios
At-home cervical cancer test rolls out in California
The first FDA-approved at-home cervical cancer screening device launched this week in California. Why it matters: Cervical cancer is largely preventable, yet 1 in 4 U.S. women aren't up to date on screenings for the disease, per the CDC. Teal Health's goal is to make the testing experience feel less invasive than a Pap smear, which can often cause pain. Driving the news: The Teal Wand allows people to self-collect a vaginal sample to test for HPV, the virus that causes nearly all cervical cancers. The San Francisco women's health company spearheading the device says it uses the same HPV test used in clinics and merely differs in the method of collection. The big picture: California records about 7.3 cervical cancer cases per 100,000 people every year, slightly under the national rate of 7.5. The incidence rate varies among racial groups, however, with Hispanics generally seeing higher figures. Nationwide, Black and Indigenous people also experience higher rates of cervical cancer and mortality compared to white women. "Several studies have shown that the availability of self-screening can boost participation in cervical cancer screening among underscreened persons—a population most likely to benefit in terms of cancer prevention," UCSF obstetrician-gynecologist George F. Sawaya told Axios via email. In 2023, cervical cancer screenings in the U.S. remained 14% lower than pre-pandemic levels, per a March journal article. Yes, but: It's equally critical to ensure those with positive test results get reliable follow-ups and treatment, Sawaya added. How it works: To take a sample, the wand — similar to a tampon in its dimensions — is inserted into the vagina and deploys a sponge to collect cells from the cervix. Once the sponge is extracted, it's placed in a vial and mailed to the lab. Teal medical providers then review the results and follow up via telehealth. The kit, which is shipped to your door, is available for purchase online and costs $99 with in-network insurance and $249 via credit card or HSA/FSA payment. By the numbers: Self-collected samples using the wand have proven to detect cervical precancer 96% of the time, similar to clinician-collected ones, Teal Health's 16-site clinical trials found. Eighty-six percent of participants said they'd be more likely to stay up to date with screenings if they could do it at home, per the trials. What they're saying: A lot of people don't recognize the importance of getting tested regularly because it's not always clear what a Pap smear is for, Teal Health co-founder and CEO Kara Egan told Axios. Lack of appointments, time conflicts and discomfort with the exam are also top reasons for not screening, Egan added. The wand was designed to alleviate those concerns, she said, offering the "same accuracy, but just comfortably and privately from home."
Yahoo
2 hours ago
- Yahoo
Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH
Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy® (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced calorie diet and increased physical activity. The accelerated approval is based on part 1 of the ESSENCE trial, in which Wegovy® demonstrated a statistically significant and superior improvement in liver fibrosis with no worsening of steatohepatitis, as well as resolution of steatohepatitis with no worsening of liver fibrosis compared to placebo. The clinical data from ESSENCE showed that at week 72, 36.8% of people treated with Wegovy® achieved improvement in liver fibrosis with no worsening of steatohepatitis compared to 22.4% treated with placebo. 62.9% of people treated with Wegovy® achieved resolution of steatohepatitis with no worsening of liver fibrosis compared to 34.3% treated with placebo. 'Wegovy® is now uniquely positioned as the first and only GLP-1 treatment approved for MASH, complementing the already proven weight loss, cardiovascular benefits and extensive body of evidence linked to semaglutide,' said Martin Holst Lange, executive vice president, chief scientific officer and head of Research and Development, at Novo Nordisk. 'MASH represents a significant health burden, with one in three people with overweight or obesity worldwide affected. In the US alone, around 22 million people are estimated to live with MASH. With the approval of Wegovy® for MASH, we provide a new treatment to people living with MASH that not only halts the disease activity but helps reverse the damage caused to the liver.' As of today, Wegovy® is available in the US for the treatment for MASH. About MASH Metabolic dysfunction-associated steatohepatitis (MASH) is a serious, progressive, metabolic disease affecting the liver, which can be fatal if not properly managed. More than 250 million people live with MASH and the number of individuals in advanced stages of the disease is expected to double by 2030. Of those who are currently overweight or living with obesity, more than one in three are also living with MASH. People living with MASH often experience few or no specific symptoms in the early stages of the disease, which often results in delayed diagnosis. The risk of progression to advanced liver disease, including liver cancer, is higher in people living with MASH than in the general population. About the ESSENCE trial ESSENCE is a phase 3 trial evaluating the effect of once-weekly subcutaneous semaglutide 2.4 mg in adults with metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis (stage 2 or 3). ESSENCE is a two-part trial where 1,200 planned participants were randomised 2:1 to receive semaglutide 2.4 mg or placebo, on top of standard of care for 240 weeks. In part 1, the objective was to demonstrate that treatment with semaglutide 2.4 mg improves liver histology at 72 weeks based on biopsy sampling from the first 800 randomised patients. In part 2, the objective is to demonstrate that treatment with semaglutide 2.4 mg lowers the risk of liver-related clinical events compared to placebo in adults with MASH and moderate to advanced liver fibrosis at 240 weeks. Based on part 1 of the ESSENCE trial, Novo Nordisk has also filed for regulatory approval in the EU in February 2025, with a subsequent filing in Japan in May 2025. Part 2 of the ESSENCE trial is expected to read out in 2029. About Wegovy® (semaglutide 2.4 mg) The FDA initially approved Wegovy® in 2021 with a reduced calorie meal plan and increased physical activity to help adults with obesity, or adults with excess weight (overweight) who also have weight-related medical problems to lose weight and keep the weight off. The indication was expanded in 2022 to include children aged 12 years and older with obesity. In 2024, Wegovy® was approved to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and either obesity or overweight. Today, the FDA granted accelerated approval for Wegovy® for a new patient population for the treatment of MASH in adults with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 78,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information: Media: Ambre James-Brown +45 3079 9289abmo@ Liz Skrbkova (US)+1 609 917 0632lzsk@ Investors: Jacob Martin Wiborg Rode +45 3075 5956 jrde@ Sina Meyer +45 3079 6656 azey@ Frederik Taylor Pitter (US) +1 609 613 0568 fptr@ Max Ung +45 3077 6414 mxun@ Publication of inside information pursuant to Market Abuse Regulation, Article 17. Attachment CA250815-MASH-US-label-update
